PDS Biotechnology Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PDSB research report →
Companywww.pdsbiotech.com
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma.
- CEO
- Frank K. Bedu-Addo
- IPO
- 2015
- Employees
- 24
- HQ
- Princeton, NJ, US
Price Chart
Valuation
- Market Cap
- $57.49M
- P/E
- -1.71
- P/S
- 0.00
- P/B
- 0.01
- EV/EBITDA
- 581.70
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -3.40%
- ROIC
- -0.15%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-34,495,505 · 8.28%
- EPS
- $-0.74 · 28.16%
- Op Income
- $-31,543,959
- FCF YoY
- -79057.52%
Performance & Tape
- 52W High
- $1.92
- 52W Low
- $0.51
- 50D MA
- $0.94
- 200D MA
- $0.94
- Beta
- 1.50
- Avg Volume
- 835.52K
Get TickerSpark's AI analysis on PDSB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 12, 26 | BEDU-ADDO FRANK | other | 548,782 |
| Jan 12, 26 | CONN GREGORY | other | 150,000 |
| Jan 12, 26 | Shepard Kirk V. | other | 300,000 |
| Jan 12, 26 | Boesgaard Lars | other | 300,000 |
| Jan 12, 26 | Brown Spencer D. | other | 300,000 |
| Jan 12, 26 | Toutain Stephan | other | 300,000 |
| Jan 12, 26 | Freitag Gregory Gene | other | 54,876 |
| Jan 12, 26 | Iliev Ilian | other | 54,876 |
| Jan 12, 26 | Ali-Jackson Kamil | other | 54,876 |
| Jan 12, 26 | BRAWLEY OTIS W | other | 54,876 |
Our PDSB Coverage
We haven't published any research on PDSB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PDSB Report →